Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 8:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 37 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Naproxen-matching placebo Clear all
Completed Phase 3 Interventional Results available

Evaluate Analgesic/Sedative Efficacy of Naproxen Sodium and Diphenhydramine in Patients With Postsurgical Dental Pain

NCT01280591
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Naproxen sodium 440 mg / DPH 50 mg (BAY98-7111), Naproxen sodium 220 mg / DPH 50 mg (BAY98-7111), Naproxen sodium 440 mg (BAYH6689), DPH 50 mg
Drug
Lead sponsor
Bayer
Industry
Eligibility
12 Years to 45 Years
Enrollment
712 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Austin, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 7, 2015 · Synced Sep 23, 2026, 8:03 PM EDT
Completed Phase 2 Interventional Results available

Study Evaluating the Analgesic Efficacy and Safety of ADL5859 in Participants With Rheumatoid Arthritis

NCT00626275
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
ADL5859, Naproxen, Placebo
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 75 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
8
States / cities
Trumbull, Connecticut • Daytona Beach, Florida • Wheaton, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2015 · Synced Sep 23, 2026, 8:03 PM EDT
Completed Phase 2 Interventional Results available

Study to Find Out the Optimal Dose of Caffeine in the Combination Tablet of Naproxen Sodium and Caffeine in Patients Experiencing Moderate to Severe Pain After Having Wisdom Teeth Removed

NCT04132336
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Naproxen sodium/Caffeine (BAY2880376), Naproxen sodium (Aleve), Caffeine, Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
16 Years and older
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 31, 2021 · Synced Sep 23, 2026, 8:03 PM EDT
Completed Phase 3 Interventional

Study Of Treximet, Formerly Known as Trexima, In The Acute Treatment Of Multiple Migraine Attacks

NCT00240617
View directory record Official record
Conditions
Migraine Disorders
Interventions
sumatriptan succinate/naproxen sodium, placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
623 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
52
States / cities
Anniston, Alabama • Tuscaloosa, Alabama • Mesa, Arizona + 48 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2016 · Synced Sep 23, 2026, 8:03 PM EDT
Completed Phase 3 Interventional Results available

Tanezumab In Osteoarthritis Of The Knee (2)

NCT00830063
View directory record Official record
Conditions
Arthritis, Osteoarthritis
Interventions
tanezumab 10 mg, tanezumab 5 mg, naproxen, placebo
Biological · Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
832 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
94
States / cities
Anniston, Alabama • Mesa, Arizona • Paradise Valley, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Sep 23, 2026, 8:03 PM EDT
Completed Phase 3 Interventional Results available

A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 2 of 2)

NCT00382993
View directory record Official record
Conditions
Migraine Disorders
Interventions
Placebo, Combination Product (sumatriptan succinate/naproxen sodium)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
28
States / cities
Jasper, Alabama • Oceanside, California • San Francisco, California + 25 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Sep 23, 2026, 8:03 PM EDT
Completed Phase 3 Interventional Results available

Migraine Study in Adolescent Patients

NCT00843024
View directory record Official record
Conditions
Migraine Disorders
Interventions
Sumatriptan and Naproxen Sodium, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years to 17 Years
Enrollment
589 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
79
States / cities
Gilbert, Arizona • Litchfield Park, Arizona • Phoenix, Arizona + 71 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2017 · Synced Sep 23, 2026, 8:03 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout and Moderate Renal Impairment

NCT02128490
View directory record Official record
Conditions
Gout, Moderate Renal Impairment
Interventions
Febuxostat IR, Febuxostat XR, Febuxostat placebo, Colchicine, Naproxen, Lansoprazole
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
89
States / cities
Birmingham, Alabama • Muscle Shoals, Alabama • Phoenix, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Sep 23, 2026, 8:03 PM EDT
Completed Phase 4 Interventional

Safety and Efficacy of Celecoxib Versus Placebo in the Treatment of Knee Osteoarthritis in Patients Who Were Unresponsive to Naproxen and Ibuprofen

NCT00638807
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Celecoxib, Placebo
Drug · Other
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
40 Years and older
Enrollment
388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
33
States / cities
Birmingham, Alabama • Buena Park, California • Denver, Colorado + 28 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Sep 23, 2026, 8:03 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Human Experimental Models of Pain (HEMP)

NCT07549490
View directory record Official record
Conditions
Acute Pain
Interventions
Placebo, Naproxen, Pregabalin
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years to 100 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Sep 23, 2026, 8:03 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Gefapixant (MK-7264) in Women With Endometriosis-Related Pain (MK-7264-034)

NCT03654326
View directory record Official record
Conditions
Endometriosis-related Pain
Interventions
Gefapixant, Placebo, Naproxen
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
30
States / cities
Birmingham, Alabama • Chandler, Arizona • Scottsdale, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2024 · Synced Sep 23, 2026, 8:03 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Mechanistic Characterization of Uterine Pain

NCT04145518
View directory record Official record
Conditions
Dysmenorrhea (Disorder), Dysmenorrhea Primary, Dysmenorrhea Secondary, Endometrial Diseases, Leiomyoma, Fibroid Uterus
Interventions
Naproxen Sodium, Placebo
Drug
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
183 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Sep 23, 2026, 8:03 PM EDT
Completed Phase 3 Interventional

Treximet (Sumatriptan/Naproxen Sodium), Formerly Known as TREXIMA, for Menstrual Migraine in Women With Dysmenorrhea

NCT00329459
View directory record Official record
Conditions
Migraine Disorders
Interventions
sumatriptan succinate/naproxen sodium, placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
34
States / cities
Mesa, Arizona • Little Rock, Arkansas • Fair Oaks, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2016 · Synced Sep 23, 2026, 8:03 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout

NCT02139046
View directory record Official record
Conditions
Gout
Interventions
Febuxostat IR, Febuxostat XR, Febuxostat placebo, Colchicine, Naproxen, Lansoprazole
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
1,790 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
192
States / cities
Binghamton, Alabama • Birmingham, Alabama • Huntsville, Alabama + 189 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Sep 23, 2026, 8:03 PM EDT
Completed Phase 4 Interventional Results available

Are Opioids Needed After ACL Reconstruction

NCT04285853
View directory record Official record
Conditions
Anterior Cruciate Ligament Rupture
Interventions
Oxycodone, Placebo oral tablet
Drug
Lead sponsor
Emory University
Other
Eligibility
14 Years to 40 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
3
States / cities
Atlanta, Georgia • Tucker, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Sep 23, 2026, 8:03 PM EDT
Completed Phase 4 Interventional Results available

A Trial to Compare the Duration of Analgesic Efficacy and Safety of Naproxen Sodium Tablets and Ibuprofen Tablets in Postsurgical Dental Pain

NCT03404206
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Naproxen Sodium (Aleve, BAY117031), Ibuprofen (Advil), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
16 Years to 40 Years
Enrollment
387 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 17, 2019 · Synced Sep 23, 2026, 8:03 PM EDT
Completed Phase 3 Interventional

Treximet (Sumatriptan/Naproxen Sodium), Formerly Known as Trexima, In The Acute Treatment Of Multiple Migraine Attacks

NCT00240630
View directory record Official record
Conditions
Migraine Disorders, Migraine
Interventions
sumatriptan succinate/naproxen sodium, placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
646 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
50
States / cities
Chandler, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 45 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2015 · Synced Sep 23, 2026, 8:03 PM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate Arthroplasty Specimens for Osteoarthritis of the Knee and Hip

NCT03949673
View directory record Official record
Conditions
Osteoarthritis, Knee, Osteoarthritis, Hip
Interventions
Fasinumab, Naproxen, Diclofenac, Celecoxib, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
6
States / cities
Phoenix, Arizona • Littleton, Colorado • Jacksonville, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2023 · Synced Sep 23, 2026, 8:03 PM EDT
Completed Phase 4 Interventional

Efficacy and Safety of Celecoxib Versus Placebo in the Treatment of Patients With Osteoarthritis of the Knee Who Were Unresponsive to Naproxen and Ibuprofen

NCT00640627
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Celecoxib, Placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
40 Years and older
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
30
States / cities
Phoenix, Arizona • Tucson, Arizona • Long Beach, California + 27 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Sep 23, 2026, 8:03 PM EDT
Completed Phase 3 Interventional Results available

A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 1 of 2)

NCT00383162
View directory record Official record
Conditions
Migraine Disorders
Interventions
Combination Product (sumatriptan succinate / naproxen sodium), Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
26
States / cities
Fresno, California • Newport Beach, California • Santa Monica, California + 23 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Sep 23, 2026, 8:03 PM EDT
Completed Phase 2 Interventional

Analgesic Efficacy and Safety of V116517 in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis (OA) of the Knee

NCT01688934
View directory record Official record
Conditions
Osteoarthritis, Knee, Pain
Interventions
V116517 50-mg tablets, V116517 30-mg tablets, Naproxen 500-mg capsules, Placebo
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
40 Years to 80 Years
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
18
States / cities
Tucson, Arizona • Boynton Beach, Florida • DeLand, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2013 · Synced Sep 23, 2026, 8:03 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Study to Evaluate Efficacy and Safety of IW-6118 in Patients Undergoing Third Molar Extraction

NCT01107236
View directory record Official record
Conditions
Healthy
Interventions
IW-6118, Matching Placebo, Naproxen Sodium
Drug
Lead sponsor
Ironwood Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 30 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 10, 2022 · Synced Sep 23, 2026, 8:03 PM EDT
Completed Phase 2 Interventional Results available

To Determine the Safety, Tolerability, Pharmacokinetics and Effect on Pain of a Single Intra-articular Administration of Canakinumab in Patients With Osteoarthritis in the Knee

NCT01160822
View directory record Official record
Conditions
Osteoarthritis
Interventions
Canakinumab, Placebo to canakinumab, Naproxen, Placebo to Naproxen
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years to 80 Years
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
8
States / cities
Anniston, Alabama • Mesa, Arizona • San Diego, California + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2012 · Synced Sep 23, 2026, 8:03 PM EDT
Completed Phase 4 Interventional

Safety and Efficacy of Celecoxib Versus Naproxen in the 6-month Treatment of Knee Osteoarthritis

NCT00643799
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Celecoxib, Naproxen, Placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
40 Years and older
Enrollment
586 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
51
States / cities
Montgomery, Alabama • Phoenix, Arizona • Tempe, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Sep 23, 2026, 8:03 PM EDT